Last reviewed · How we verify

NCT02902133

Acetazolamide to Prevent Post Operative CSF Leak

Withdrawn Phase 2 Last updated 21 April 2020
What this trial tests

Phase 2 trial testing Acetazolamide in Cerebrospinal Fluid Leak. Withdrawn.

Timeline
1 September 2016
Primary endpoint
1 September 2021
1 September 2021

Quick facts

Lead sponsorUniversity of Miami
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 September 2016
Primary completion1 September 2021
Estimated completion1 September 2021

Drugs / interventions tested

Conditions studied

Sponsor

University of Miami

Who can join

18 and older, any sex, with Cerebrospinal Fluid Leak. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to test the use of Acetazolamide in preventing post-operative cerebrospinal fluid leak in patients having endoscopic skull base surgery (it is a surgery performed through the nose and sinus).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Acetazolamide

Trials testing the same drug.

Other University of Miami trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02902133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing